Health
Immuno Cure kick off Phase I Clinical Trial in Shenzhen
A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS HONG KONG, Feb. 16, 2023 /PRNewswire/ -- Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in PD-1-Enhanced DNA vaccines and immunotherapies,announced the ...
2023-02-16 20:36
4746
H/Advisors Public Affairs, Powered by Havas Health & You, to Launch Fully Integrated U.K./EU/U.S. Public Affairs Practice
BRUSSELS, Feb. 16, 2023 /PRNewswire/ -- To help brands and clients stay on the pulse of the world's rapidly changing political and regulatory health landscape, H/Advisors, the global strategic advisory offering of the Havas Network, today announced the launch of a fully integrated health care pub...
2023-02-16 19:00
1854
Alibaba Entrepreneurs Fund Launches JUMPSTARTER 2023 Global Pitch Competition
Newly added HKD1 million cash prize and a maximum total investment of up to USD5 million Encourage start-ups to integrate UN Sustainable Goals into businesses HONG KONG, Feb. 16, 2023 /PRNewswire/ -- Alibaba Hong Kong Entrepreneurs Fund ("AEF") today announced the JUMPSTARTER 2023 Global Pitch C...
2023-02-16 18:23
2914
Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B
HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the oral presentation at the 2023 annual meeting of the Asian Pacific Association for the Study of the Liver ("APASL Annual Meeting 2023") demonstrates that ASC22 (Envafol...
2023-02-16 17:10
2856
Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck
HELSINGBORG, Sweden, Feb. 16, 2023 /PRNewswire/ -- AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. Me...
2023-02-16 15:00
1800
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands, Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA) Committ...
2023-02-16 14:00
2422
111, Inc. Hosts Hua Medicine Launches First Official Flagship Store
SHANGHAI, Feb. 16, 2023 /PRNewswire/ -- On February 15, 2023, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, announced that during the HuaTangNing® Market Launch for Innovative Commerce Cooperation, Dr.Yu Gang, Co-founder and Executive...
2023-02-16 13:33
1923
GNOMIX: An Australian Case Study to Democratise Clinical Applications of Genomics with MGI's DNBSEQ™ Platforms
BRISBANE, Australia, Feb. 16, 2023 /PRNewswire/ -- GNOMIX
2023-02-16 12:00
2537
Boan Biotech's Investigational Long-acting Anti-IL-4Rα Antibody BA2101 Administered for First Patient in Phase I Clinical Trial
YANTAI, China, Feb. 16, 2023 /PRNewswire/ -- Luye Pharma Group today announced that BA2101, an investigational anti-IL-4Rα antibody developed by its subsidiary Boan Biotech, has been administered for the first patient in a Phase I clinical trial. Recognized as a Class 1 innovative biological prod...
2023-02-16 08:15
3279
WuXi AppTec Named "Industry Mover" in S&P Global Sustainability Yearbook 2023
SHANGHAI, Feb. 15, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced today that it ...
2023-02-16 08:00
1847
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis
ROCKVILLE, Md. and SUZHOU, China, Feb. 16, 2023 /PRNewswire/ -- Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology ...
2023-02-16 08:00
3214
Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery
Collaboration to develop 3D in vitro models of the brain for the discovery of
therapeutic candidates using Inventia's novel 3D cell culture platform, RASTRUM™
SYDNEY, Feb. 15, 2023 /PRNewswire/ -- February 16, 2023, Inventia Life Science
2023-02-16 06:00
2289
Tetracore Announces USDA Purchase of ASF and FMD Diagnostic Test Kits
ROCKVILLE, Md., Feb. 16, 2023 /PRNewswire/ -- Tetracore, Inc. (Tetracore®) is pleased to announce its partnership with the United States Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) to provide a stock of PCR kits for both African Swine Fever (ASF) and Foo...
2023-02-16 04:35
2859
Bioved Pharmaceuticals, Inc. announces the launch of its proprietary Natural Products for Animal Health, with its Shwan Ayurved™ science
SAN JOSE, Calif., Feb. 16, 2023 /PRNewswire/ -- Bioved Pharmaceuticals, Inc. is pleased to announce the launch of its scientifically validated Natural Animal Health products from the science of Ayurveda. Bioved is a Discovery Platform for safe and effective plant-based nutraceuticals, dietary sup...
2023-02-16 01:00
2625
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Randomized, double-blind, placebo-controlled study to evaluate efficacy of novel pan-GI prokinetic in patients with gastroparesis ROSCREA, Ireland and FREIBURG, Germany, Feb. 15, 2023 /PRNewswire/ -- Renexxion Ireland Limited, a private biopharmaceutical company committed to delivering innovativ...
2023-02-15 21:30
2708
Flagship Biosciences Applauded by Frost & Sullivan for Changing Biomarker Analysis to Find Biomarkers that Aid Drug Development and Diagnostics
Digital pathology solutions are increasingly used in the preclinical and clinical development phases, particularly toxicologic pathology and clinical trials, speeding up the process and curtailing expenses. SAN ANTONIO, Feb. 15, 2023 /PRNewswire/ -- Frost & Sullivan assessed the artificial intel...
2023-02-15 21:00
1977
Kubota Tractor Corporation Implements Syncron For Streamlined Retail Inventory Management and Exceptional Dealer Network Service
Leading distributor of agricultural and construction machinery equipment selects Syncron Retail Inventory for optimized dealer inventory management that aligns aftermarket strategies with dealer networks for superior customer service. CHICAGO, Feb. 15, 2023 /PRNewswire/ -- Syncron today announce...
2023-02-15 21:00
2492
Internationally Renowned Orthopaedic Surgeon Thought Leaders Join Formus Labs' Clinical Advisory Board
AUCKLAND, New Zealand, Feb. 15, 2023 /PRNewswire/ -- Formus Labs, creator of the first automated 3D AI-enabled pre-operative planner for joint replacement surgeries, today announces that arthroplasty experts DrJ. Bohannon Mason, Dr. Atul Kamath, and Dr. James A. Germano will join its clinical adv...
2023-02-15 21:00
1703
AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider
NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platfo...
2023-02-15 21:00
3250
Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02
* The first Chinese biosimilar approved in both China and the EU, and potentially to be approved in the U.S. - * HLX02 (trastuzumab for injection, trade name in China: HANQUYOU; trade name inEurope: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®) has been approved in more than 3...
2023-02-15 16:49
2795
Week's Top Stories
Most Reposted
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
[Picked up by 350 media titles]
2024-06-19 11:00
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
[Picked up by 335 media titles]
2024-06-20 16:24
k-ID Closes $45 Million Series A from Andreessen Horowitz and Lightspeed Venture Partners to Set a New Global Benchmark for Age-appropriate Gaming Experiences
[Picked up by 318 media titles]
2024-06-25 21:00
New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers
[Picked up by 317 media titles]
2024-06-19 08:05THEIR ROYAL HIGHNESSES THE DUKE AND DUCHESS OF EDINBURGH CELEBRATE THE GRAND OPENING OF THE PENINSULA LONDON, BELGRAVIA
[Picked up by 313 media titles]
2024-06-19 11:38
Most Read
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
2024-06-19 11:00
15695
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
2024-06-20 16:24
13476
THEIR ROYAL HIGHNESSES THE DUKE AND DUCHESS OF EDINBURGH CELEBRATE THE GRAND OPENING OF THE PENINSULA LONDON, BELGRAVIA
2024-06-19 11:38
9533
New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers
2024-06-19 08:05
9442
